Immune Regulatory Mediators in Plasma from Patients with Acute Decompensation are Associated With 3-month Mortality by Becares, N et al.
Journal Pre-proof
Immune Regulatory Mediators in Plasma from Patients with Acute Decompensation
are Associated With 3-month Mortality
Natalia Becares, Suvi Härmälä, Louise China, Romain A. Colas, Alexander A.
Maini, Kate Bennet, Simon S. Skene, Zainib Shabir, Jesmond Dalli, Alastair O’Brien
PII: S1542-3565(19)30911-5
DOI: https://doi.org/10.1016/j.cgh.2019.08.036
Reference: YJCGH 56709
To appear in: Clinical Gastroenterology and Hepatology
Accepted Date: 9 August 2019
Please cite this article as: Becares N, Härmälä S, China L, Colas RA, Maini AA, Bennet K, Skene
SS, Shabir Z, Dalli J, O’Brien A, Immune Regulatory Mediators in Plasma from Patients with Acute
Decompensation are Associated With 3-month Mortality, Clinical Gastroenterology and Hepatology
(2019), doi: https://doi.org/10.1016/j.cgh.2019.08.036.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2019 by the AGA Institute
1 
 
Title: Immune Regulatory Mediators in Plasma from Patients with Acute Decompensation 
are Associated With 3-month Mortality 
Short title: Inflammatory responses and mortality in AD/ACLF 
 
Natalia Becares1*, Suvi Härmälä2, Louise China1, Romain A. Colas3, Alexander A. Maini1, 
Kate Bennet4, Simon S. Skene4#, Zainib Shabir4,  Jesmond Dalli3, Alastair O’Brien1 
 
1Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, University 
College London, London, United Kingdom. 
2Institute of Health Informatics, University College London, London, United Kingdom. 
3Lipid Mediator Unit, Center for Biochemical Pharmacology, William Harvey Research 
Institute, Barts and The London School of Medicine, Queen Mary University of London, 
Charterhouse Square, London, United Kingdom. 
4Comprehensive Clinical Trials Unit, University College London, London, United Kingdom. 
*contact: Rayne Institute, 5 University Street, London WC1E 6JF, 
natalia.becares.13@ucl.ac.uk, Phone: +44 (0) 2076796192  
#New address: School of Biosciences and Medicine, University of Surrey, Surrey, United 
Kingdom. 
 
FINANCIAL SUPPORT 
This study was supported by the Health Innovation Challenge fund (Wellcome Trust and 
Department of Health) (grant no. 164699) and the Rosetrees Trust (award no. JS15/M728). 
SH is supported by the UK Biotechnology and Biological Sciences Research Council grant 
number BBSRC BB/M009513/1. 
 
 
 
LIST OF ABBREVIATIONS 
2 
 
Acute decompensation: AD; Acute-on-chronic Liver Failure: ACLF; Cirrhosis-associated 
immune dysfunction: CAID; C-Reactive Protein: CRP; Docosahexaenoic acid: DHA; 
Docosapentaenoic acid: DPA; Eicosapentaenoic acid: EPA; Enzyme-linked immunosorbent 
sandwich assay: ELISA; Human albumin solution: HAS; Interleukin: IL; Intravenous: IV; Lipid 
mediator: LM; LPS-binding protein: LBP; Lipopolysaccharide: LPS; Model for End Stage 
Liver Disease: MELD; Monocyte-derived-macrophage: MDM; Peripheral blood mononuclear 
cells: PBMC; Prostaglandin E2: PGE2; Randomised controlled trial: RCT; Specialized pro-
resolving mediators: SPMs; Tumor Necrosis Factor: TNF; White cell count: WCC 
 
CONFLICT OF INTEREST 
None of the authors have any conflicts of interest 
 
AUTHOR CONTRIBUTIONS 
AM and LC obtained and processed the samples used in this study. SV and LC performed 
clinical characteristic analysis. NB performed the majority of the laboratory work assisted by 
LC. JD and RAC performed the lipid metabolomic work. SS provided statistical oversight and 
SS and KB performed the statistical analyses for the clinical trial. ZS managed the clinical 
trial assisted by LC. NB, LC and AOB interpreted the data and NB prepared figures. NB and 
AOB designed the study and wrote the manuscript. LC, JD and SV helped with data 
interpretation. AOB supervised all aspects of the work, designed the clinical trial and 
obtained funding. All authors approved the final manuscript. 
 
 
 
 
 
Abstract:  
3 
 
Background & Aims: Infection is a common cause of death in patients with cirrhosis. We 
investigated the association between the innate immune response and death within 3 months 
of hospitalization.  
 
Methods: Plasma samples were collected on days 1, 5, 10, and 15 from participants recruited 
into the albumin to prevent infection in chronic liver failure feasibility study. Patients with 
acute decompensated cirrhosis were given albumin infusions at 10 hospitals in the United 
Kingdom. Data were obtained from 45 survivors and 27 non-survivors. We incubated 
monocyte-derived macrophages from healthy individuals with patients’ plasma samples and 
measured activation following lipopolysaccharide administration, determined by secretion of 
tumor necrosis factor and soluble mediators of inflammation. Each analysis included samples 
from 4 to 14 patients. 
 
Results: Plasma samples from survivors vs non-survivors had different inflammatory 
profiles. Levels of prostaglandin E2 were high at times of patient hospitalization and 
decreased with albumin infusions. Increased levels of interleukin 4 (IL4) in plasma collected 
at day 5 of treatment were associated with survival at 3 months. Incubation of monocyte-
derived macrophages with day 5 plasma from survivors, pre-incubated with a neutralizing 
antibody against IL4, caused a significant increase in tumor necrosis factor production to the 
level of non-survivor plasma. Although baseline characteristics were similar, non-survivors 
had higher white cell counts and levels of C-reactive protein and renal dysfunction. 
 
Conclusions: We identified profiles of inflammatory markers in plasma that are associated 
with 3-month mortality in patients with acute decompensated cirrhosis given albumin. 
Increases in prostaglandin E2 might promote inflammation within the first few days after 
hospitalization, and increased levels of plasma IL4 at day 5 are associated with increased 
survival. Clinicaltrialsregister.eu: EudraCT 2014-002300-24 
 
KEY WORDS:  TNF, MDM, death, immune response 
 
Need to Know 
 
Background: Infection is a common cause of death in patients with cirrhosis. We investigated 
the association between the innate immune response and death within 3 months of 
hospitalization. 
 
Findings: In an analysis of plasma samples from patients given albumin infusions for acute 
decompensated cirrhosis or acute on chronic liver failure, we found differences in levels of 
cytokines in patients who survived 30 days vs patients who did not. Plasma from survivors 
had increased levels of interleukin 4, which reduced activation of monocyte-derived 
macrophages. Plasma levels of prostaglandin E2 decreased with albumin treatment. 
 
Implications for Patient Care: Differences in plasma levels of cytokines, such as 
prostaglandin E2 and interleukin 4, might affect response to infections or treatment in 
patients with acute decompensated cirrhosis or acute on chronic liver failure. 
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INTRODUCTION 
The most severe clinical presentation of liver cirrhosis is acute decompensation (AD) or 
Acute-on-Chronic-Liver Failure (ACLF)1. Patients are highly prone to bacterial infection 
secondary to immune dysregulation2 termed ‘cirrhosis-associated immune dysfunction’ or 
CAID2. CAID causes a paradoxical phenotype in ACLF that combines exaggerated systemic 
inflammation with immune suppression. Potential immune restorative therapies should aim 
to improve immune function without worsening systemic inflammation; however, despite 
detailed work describing the ACLF phenotype3,4 and its high clinical relevance, there are no 
licensed treatments to improve immune dysfunction. 
We previously identified Prostaglandin E2 (PGE2) as a potential causative immune 
suppressive molecule 5,6. Albumin has been reported to bind and catalyse PGE2 inactivation 
7
 and we found that as albumin levels decreased in AD/ACLF, PGE2 may be more 
bioavailable and injurious. We therefore proposed transfusing 20% human albumin solution 
(HAS) to antagonise the effects of PGE2 6 and prevent infection in our randomised controlled 
trial (RCT), ATTIRE (Albumin to prevent infection in chronic liver failure). In the single arm 
ATTIRE feasibility study of 79 patients at 10 sites, we demonstrated that 20% HAS infusions 
restored serum albumin levels to >30 g/dl and improved ex vivo immune function in 
AD/ACLF patients by day 3 of study participation through antagonism of PGE2 6,8. However 
this study included samples from only the first few days of admission and was not linked with 
clinical outcome.  
We therefore performed this follow-up study examining the inflammatory response 
throughout admission in albumin-treated patients and linked this to outcome. We selected 
mortality at 3 months following recruitment as our primary clinical outcome in order to study 
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whether the inflammatory response throughout admission differed between survivors and 
non-survivors and potential underlying molecular mechanisms.  
Our study suggests that survivors and non-survivors exhibited distinct temporal profiles in 
immune function that corresponded with changes in white cell count and we propose a novel 
role for interleukin (IL)-4 in this process.  
 
METHODS 
Patient studies 
Patients were recruited as part of the ATTIRE feasibility study, all were treated with daily 
intravenous (IV) 20% HAS if serum albumin <30g/L during the trial treatment period (up to 
14 days post recruitment). All patients admitted to hospital with AD/severe worsening of liver 
cirrhosis complications, aged >18years, serum albumin <30g/L, predicted hospital admission 
by attending clinicians greater than 5 days and for full active management at admission were 
eligible. Patients were recruited within 72 hours of hospitalisation; full criteria are described 
elsewhere 8,9. We sought written informed patients consent from patients or representatives 
if they lacked capacity. Research ethical approval was granted by London-Brent research 
ethics committee (ref:15/LO/0104). Plasma samples were randomly selected corresponding 
to days 1 (pre-treatment), 5, 10 and 15 (end of trial). Survivor and non-survivor groups were 
divided a priori based on death during 3 months follow up at local National Health Service 
sites. Data were obtained from a maximum 45 survivors and 27 non-survivors at baseline. 
Experimental studies were performed on samples available with n values in figure legends. 
The trial is registered with European Medicines Agency (EudraCT 2014-002300-24) and 
adopted by NIHR (ISRCTN14174793). All authors had access to the study data and 
reviewed and approved the final manuscript. 
Laboratory analysis are described in Supplemental Material. For multiple comparisons, 
significance was assessed by one-way ANOVA followed by Bonferroni adjusted pairwise t-
tests. White cell count and CRP followed an approximately log-normal distribution each day 
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and values were therefore transformed (ln, natural logarithm) for statistical analyses. 
Number of tests were adjusted for the number of trial days. Differences in mean values 
between survivors and non-survivors were compared using two-tailed t-test allowing for 
unequal variances with Bonferroni correction. 
 
RESULTS 
Distinct plasma-mediated inflammatory response phenotypes during hospitalisation 
in albumin-treated patients differentiated between survivors and non-survivors  
We investigated the temporal profile of inflammatory responses in participants throughout 
the trial period, by examining the effect of plasma from days 1, 5, 10 and 15 on healthy 
monocyte derived macrophages (MDMs)5,6. MDMs were incubated with plasma from 
AD/ACLF patients or healthy volunteers and subsequent activation in response to LPS 
quantified by assessing levels of secreted TNF-α. As previously6, plasma from AD/ACLF 
patients at day 1 reduced MDM TNF-α production  compared to healthy volunteer plasma 
(Figure 1A). This immune suppressive effect waned during hospitalisation and, following 
targeted HAS infusions, reached healthy volunteer levels by end of trial treatment period 
(day 15) (Fig 1A). MDM production of the anti-inflammatory cytokine IL-10 at 24 hours post-
stimulation mirrored this pattern with levels higher at day 1 and returning to those produced 
by cells incubated with healthy plasma by day 15 (Fig 1B).  
When samples were divided into survivor and non-survivors, this observed pattern of 
immune activation differed between groups. MDMs sensitised with day 1 non-survivor 
plasma demonstrated a slightly lower production of TNF-α compared to survivors (Fig 1C). 
However, MDM TNF-α production in this group was rapidly and significantly restored to 
healthy levels by day 5 and maintained throughout the rest of the trial. In contrast, MDM 
TNF-α production following treatment with survivor plasma did not reach healthy plasma 
levels until day 15 of the trial (Fig 1C). Indeed, there was a 2.6 fold-increase in TNF-α levels 
between day 1 and day 5 in cells incubated with non-survivor plasma (p < 0.001) compared 
to 1.26 fold-increase in those treated with survivor plasma (p > 0.05). Neither patient group’s 
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plasma elicited a greater TNF-α production than healthy volunteer plasma by day 15 of trial 
(Fig 1C). These distinct patterns of inflammatory response between survivors and non-
survivors were mirrored by MDM production of IL-10 (Fig. 1B). Survivor plasma elicited a 
gradual decrease in MDM IL-10 production to reach the same level as healthy volunteer 
plasma by day 15, whereas non-survivor plasma elicited a more rapid fall in production by 
day 5, although differences did not reach significance (Fig 1D). These two inflammatory 
response phenotypes (rapid in non-survivors compared to gradual in survivors), appeared 
distinct by day 5 of the trial, marking this as a potential crucial time-frame that determines 
outcome. We therefore focused further analyses between baseline (day 1) and day 5.   
 
Both groups of patients demonstrated similar baseline clinical characteristics but 
non-survivors developed increased serum white cell counts, C-reactive protein and 
renal dysfunction  
Overall baseline patient data has been presented previously in this cohort with the majority 
having alcohol-related cirrhosis 8. Non-survivors displayed non-significantly increased Model 
for End Stage Liver Disease (MELD) scores, ACLF scores, diagnosis of infection at baseline 
and antibiotic prescription (Table 1). The number of days in trial, baseline white cell count 
(WCC) and C-Reactive protein (CRP) were similar in both groups (Table 2). Serum 
creatinine was higher in non-survivors at baseline and renal dysfunction developed solely in 
the non-survivor group (30.8%, Table 1). As the differences in laboratory inflammatory 
response appeared during the first half of the trial, we compared the WCC and CRP values 
between groups during this period (up to day 7). On day 6 where the difference in WCC 
levels between groups reached its peak (Fig. 2A) the absolute WCC levels were significantly 
higher in non-survivors (p=0.029). Relative change from baseline WCC also significantly 
differed on day 6 between survivors and non-survivors (adjusted p=0.033, corrected for 4 
tests, raw p=0.008) when values were compared.  CRP followed a similar trend with higher 
levels in non-survivors, but differences in absolute levels did not reach statistical 
8 
 
significance, however the difference in relative change from baseline CRP significantly 
differed between groups on day 4 (adjusted p=0.032, corrected for 2 tests, raw p=0.016) (Fig 
2B). Nosocomial infections developed in 10/26 non-survivors compared to 9/45 survivors 
following 48 hours of albumin treatment (p=0.19, chi-squared test). 
 
Plasma levels of albumin, LBP and albumin-PGE2 binding capacity during 
hospitalisation did not differ between survivors and non-survivors  
Volume of HAS administered during the trial did not differ between survivor and non-survivor 
groups (Table 1) and levels of circulating albumin and its binding capacity to PGE2 improved 
similarly in both groups throughout the trial (Fig 2C). Levels of plasma LPS-binding protein 
(LPB), used as a marker of endotoxin presence 10, did not differ between groups (Fig 2D).  
 
Plasma lipid mediator profiles at day 1, 5, 10 and 15 differed between survivors and 
non-survivors  
Lipid mediator (LM) analysis revealed differing trends between inflammation-initiating and 
resolution pathways in survivors and non-survivors according to day of sampling. We 
observed differences between DHA-derived Pro-resolving Lipid Mediators (SPMs) - D-series 
Resolvins (RvD1, RvD2, RvD3, RvD4, RvD5, RvD6, 17R-RvD1and 17R-RvD3), Protectins 
(PD1 and 17R-PD1) and Maresins (MaR1 and MaR2); n-3 DPA- derived SPMs - Resolvins 
(RvT1, RvT3, RvT4, RvD1n-3 DPA, RvD2n-3 DPA and RvD5n-3 DPA), Protectins (PD1n-3 
DPA) and Maresins (MaR1n-3 DPA); EPA-derived SPMs - E-series Resolvins (RvE1, RvE2 
and RvE3); and differences were observed in Arachidonic acid-derived Lipoxins (LXA4, 
LXB4, 15-epi-LXA4and 15-epi-LXB4) (Fig 3A, Supplemental Figure 1A-D).  
Using orthogonal Partial Least Square Discriminant Analysis, a regression model that 
identifies variables contributing to separation of experimental groups, we found LM profiles 
of survivors were distinct from non-survivors, demonstrated by divergent clustering of LM 
profiles for patients from each group for all intervals tested (Suppl Fig 1 A-D). Assessment of 
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the variable in importance scores, which identify the contribution of each mediator in the 
observed separation between each of the groups, demonstrated an increased concentration 
of several SPM mediators associated with non-survivors (Suppl Fig 1 A-D). Members of the 
D-series resolvin family were linked with non-survivors, although increases in absolute 
amounts of these molecules did not reach statistical significance (Suppl Table 1).  
Plasma LM profiles demonstrated PGE2 concentrations were similarly elevated levels at day 
1 (Fig 3A,B) (p=0.47) and fell substantially by day 5 in both groups (p=0.09). When cells 
incubated with day 5 plasma from both survivors and non-survivors were treated with pan-
PGE2 receptor antagonists, there was a similar increase in MDM TNF-α production (1.2-fold 
change for both groups) (Fig 3C).  
 
Elevated plasma IL-4 concentration at day 5 was associated with 3-month survival and 
was able to switch plasma-mediated inflammatory response  
We measured 30 cytokines in survivor and non-survivor plasma from days 1, 5, 10 and 15 
by multiplex analysis (Suppl Table 2). No differences were observed between groups of the 
classical inflammatory cytokines linked to ACLF prognosis 11,12, such as TNF-α, IL-6, IL-8 
and IL-10 (Suppl Figure 2A). A significant increase in IL-4 was found in survivor day 5 
plasma (Fig 3D), the period at which survivor and non-survivor plasma-mediated 
inflammatory response phenotypes appeared distinct. Western blot analysis revealed that 
peripheral blood mononuclear cells (PBMCs) from AD/ACLF patients contained detectable 
levels of IL-4 protein (Suppl Figure 2B). Subsequently, we demonstrated that MDMs 
incubated with healthy volunteer plasma that had been supplemented with increasing 
concentrations of recombinant IL-4 caused decreased TNF-α production in response to LPS 
in a dose-dependent manner (Fig. 3E). MDM cells treated with day 5-survivor plasma that 
had been pre-incubated with neutralizing anti-IL-4 antibody (black and white squared box), 
significantly increased TNF-α production and this reached the same level as seen in cells 
incubated with non-survivor plasma (light grey box) (Fig. 3F). No effect was seen with 
neutralizing anti-IL-4 antibody in experiments using non-survivor plasma (Fig. 3F). Finally, 
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we observed that IL-4 plasma concentrations at day 5 correlated negatively with baseline 
MELD score (Suppl Fig 3).  
 
DISCUSSION 
Immune function and inflammation in AD/ACLF patients has emerged as a critical area of 
research with the aim of developing treatments that improve mortality 13. Due to challenges 
associated with collecting primary cells from multiple sites, we used our ex-vivo immune 
assay to investigate plasma-mediated immune responses and sought to determine whether 
results were associated with 3-month mortality. These data demonstrate that HAS infusions 
continued to restore the plasma-mediated inflammatory response as defined by macrophage 
TNFα and IL-10 production in AD/ACLF patients to healthy volunteer levels beyond day 3 as 
shown previously 6,8. This is consistent with recent data identifying changes in plasma IL-10 
reflecting disease severity and improving following albumin treatment 4,14. Survivors and non-
survivors demonstrated distinct and unexpected plasma-mediated inflammatory response 
patterns during the trial, with non-survivors exhibiting a rapid increase of MDM activation to 
healthy levels that associated with an elevated white cell count. Despite a significant overall 
effect on our immune assay, the HAS-PGE2 interaction did not appear to differentiate 
between these inflammatory phenotypes. Intriguingly, IL-4 at day 5 was significantly 
upregulated in survivors and mechanistic analyses suggest this may also represent a 
potential therapeutic target. Finally, a failed resolution of inflammation lipid mediator 
phenotype was observed in non-survivors.  
Our novel data support a mechanistic protective role for IL-4. This cytokine has not been 
previously linked to CAID, although studies in humans and animal models support a 
protective role for elevated IL-4 in sepsis15 16 and acute lung injury 17. We demonstrated that 
manipulation of IL-4 switched immune restoration-like phenotypes between survival and non-
survival and suggest IL-4 agonism may represent a potential immune-restorative target in 
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AD/ACLF patients that develop increased circulatory inflammatory markers during 
hospitalisation.  
Previous studies demonstrated an association between high circulatory inflammatory 
markers e.g. CRP 18,19 and inflammatory cytokines at baseline 12,20,21 and increased mortality 
in AD/ACLF. In our cohort baseline clinical characteristics of the survivors and non-survivors 
were quite similar aside from serum creatinine and a non-significant increase in MELD score 
and infection rate, which may be due to the relatively small sample size. However the 
development of an elevated WCC, CRP and renal dysfunction during admission was 
significantly associated with 3 month mortality. Our work supports elevated PGE2 being 
crucial in this process early in admission and IL-4 at later timepoints, although it is likely that 
other molecules are involved.  
We previously showed that albumin treatment may alter plasma LM profiles in a small cohort 
of patients from the ATTIRE feasibility study 6. In this study Principal Component Analysis 
revealed several families of SPMs that associated with good or poor outcome using samples 
taken at different time points before and after albumin infusions. This work remains 
promising but greater numbers of patients will be required to identify specific LMs for 
potential drug development targets or to predict outcome or response to treatment. The 
observation that SPMs are also upregulated in non-survivors indicates that while SPM 
biosynthetic pathways are active in these patients, production does not limit the unbridled 
inflammatory response. This could be due to delayed engagement of biosynthetic pathways, 
dysregulated receptor expression or dysregulated downstream signalling pathways. 
Many studies have demonstrated the potential immunomodulatory properties of albumin 
5,6,22
. However differing results from recent well-conducted outpatient studies suggest patient 
response may not be uniform 23,24. All patients in this single arm study were treated with 
intravenous HAS which appeared to have a beneficial immune effect throughout 
hospitalisation by antagonising PGE2 effects. However it is possible that the differing 
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inflammatory responses observed associated with patients’ 3 month outcome may represent 
albumin treatment “successes” and “failures”. Further studies are required to determine 
whether PGE2 levels early in admission, IL4 levels at day 5 or a LM failure to resolve 
phenotype represent biomarkers or targets for a future precision medicine approach to 
improve treatment in these patients.  This was a single arm study and we were unable to 
compare findings with non-treated patients. 
Our immune assay was developed to investigate effects of plasma from AD/ACLF patients 
on macrophage function rather than primary cells, as it was not possible to collect fresh 
monocytes from multiple UK sites. However, our separate single site study has 
demonstrated an identical phenotype of reduced TNF-α production in fresh whole blood from 
AD/ACLF patients stimulated with LPS, supporting this approach 25. Furthermore our 
laboratory assay was potentially able to differentiate between survivors and non-survivors 
and mechanistic work has identified a potential novel mediator of CAID, suggesting that the 
approach has validity. The association of the inflammatory phenotype in those who died at 3 
months with development of an elevated WCC and CRP strengthens the laboratory work 
and aids potential clinical approaches in the future. Our cohort predominantly included 
patients with alcohol-driven liver disease and the laboratory analyses used samples from 
only patients with alcohol-related cirrhosis.  Therefore our findings may not be applicable to 
cohorts containing large numbers of non-alcoholic steatohepatitis or viral hepatitis patients. 
Moreover we did not have sufficient samples to extend studies to compare between AD and 
ACLF. ATTIRE stage 2, a large scale RCT at 30 sites that finishes in June 2019 26 will 
provide samples taken from patients treated with and without HAS at day 1, 5 and 10 in 
order to validate these findings and guide future immune restorative approaches in 
AD/ACLF. This will allow us to discern the potential effect of 20% HAS infusion on the 
establishment of different patterns of inflammatory responses observed and their relationship 
to survival. 
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We present novel data that describes CAID as a dynamic process and propose that the 
inflammatory response trajectory may represent the critical determinant of clinical outcome. 
Distinct plasma-mediated inflammatory responses, as defined by our laboratory assay and 
changes in WCC and CRP from baseline during the first week of hospitalisation, were 
associated with organ dysfunction and death in albumin-treated advanced liver disease 
patients. Finally our results PGE2 and IL-4 as pivotal mediators that underlie the 
inflammatory response in these patients at different time points during their hospital 
admission. 
 
FIGURE LEGENDS 
Figure 1. Distinct immune restoration phenotype associated with survival develops 
over time 
Levels of TNF-α (A, C) and IL-10 (B, D) secreted by MDMs were quantified by ELISA. Cells 
were sensitised with plasma from ATTIRE survivors, non-survivors and healthy volunteers 
for 30 minutes and stimulated with 100 ng/ml LPS for 4 (A, C) and 24 (B, D) hours. Boxes 
represent median with upper and lower quartiles. Bars represent minimum and maximum 
observations. Number of samples used for each day are written in parentheses. * p < 0.05, 
**  < 0.01, *** p < 0.001. Significance determined using one-way ANOVA and Bonferroni 
adjusted pairwise t-tests. 
 
Figure 2. Plasma levels of albumin, LBP and albumin-PGE2 binding capacity did not 
differentiate between groups 
A, B) Daily white cell counts (WCC) (A) and C-Reactive Protein (CRP) (B) in survivor (n= 10 
-38) and non-survivor (n = 6-22) groups during ATTIRE Feasibility study. Data expressed as 
mean and standard error. C) Levels of circulating albumin (g/L) (n=5-7) and percentage of 
PGE2/3H-PGE2 bound to survivor and non-survivor patient plasma protein, day 1, 5, 10 and 
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15 using equilibrium dialysis (n=3-5). D) Plasma lipopolysaccharide-binding protein (LBP) by 
ELISA in day 1 and 5 samples from survivors (n = 5-8) and non-survivors (n=7-10).  
 
Figure 3. Plasma molecule study reveals differential IL-4 levels that associate with 
survival 
A) 2-dimentional loading plot of plasma samples at day 5 (C, D). Survivors (n = 7), non-
survivors (n = 8).  
B) Levels of PGE2 in human plasma from acute decompensation patients collected at 
indicated intervals. Results expressed as pg / mL, mean ± SEM. Dotted line represents 
mean levels from healthy volunteer plasma (n = 5). p-values correspond to unpaired T-Test 
(between survivors and non-survivors at days 1 and 5). 
C) Levels of secreted TNF-α by MDMs quantified by ELISA. Cells were pre-treated with 
50µM AH6809 (EP1-3 antagonist) and 10µM MF498 (EP4 antagonist) and sensitised with 
day 5 plasma from ATTIRE survivors and non-survivors and healthy volunteers (HV) for 30 
minutes and stimulated with 100 ng/ml LPS for 4 hours. Data represent median with 25th/75th 
percentiles (n = 4-6). Bars represent minimum and maximum observations. 
D) Plasma IL-4 levels on day 1 and day 5 samples from survivors (n = 8-9) and non-
survivors (n = 7-8). Results expressed as pg / mL, mean ± SEM. * p < 0.05 determined by 
Student’s t-test. Dotted line represents mean levels from healthy volunteer plasma (n = 5). 
E, F) Levels of secreted TNF-α by MDMs quantified by ELISA. Cells were sensitised with 
healthy volunteer plasma supplemented with several concentrations of recombinant human 
(rh) IL-4 (E) or day 5 plasma from survivors and non-survivors incubated with neutralizing 
anti-IL4 antibody (F) for 30 minutes and stimulated with 100 ng/ml LPS for 4 hours (n = 4-5). 
*p < 0.05 determined by paired T-test. 
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Table 1. Patient group characteristics  
 
Survivors  Non survivors  
Median Age, range (n=number of 
patients with data) 54.6, 30-75 (45) 55.3, 24-81 (27) 
Male Sex, number (%) 32/45 (71.1%) 15/27 (55.5%) 
Baseline median MELD score, 
IQR (n) 19.8, 16.0-23.1 (38) 23.6, 17.4-28.4 (20) 
Total HAS given 
Median, IQR (n) 850, 700-1500 (44) 1000, 400-1600 (26) 
Median days in trial, IQR (n) 14, 8-15 (44) 12, 4-15 (26) 
Number with infection diagnosed 
at recruitment (%) 16/45 (35.5%) 12/26 (48%) 
Prescribed antibiotics at 
recruitment, number (%) 22/45 (49%)  17/26 (65%) 
Number with new infection during 
trial after HAS treatment for >48h 
(%) 
9/45 (20%) 10/26 (37%) 
Renal dysfunction diagnosis 
during trial (%) 0/44 (0.0%) 8/26 (30.8%) 
Alcohol consumption as aetiology 
(%) 43 (91%)  27 (100%) 
Active alcohol consumption at 
admission (%) 20 (43%)  5 (19%) 
ACLF scores, n (%) 
0 35 (77.8%) 0 17 (63%) 
1 6 (13.3%) 1 4 (14.8%) 
2 3 (6.7%) 2 3 (11.1%) 
3 1 (2.2%) 3 3 (11.1%) 
 
 
 
 
 
 
 
 
Table 2. Baseline blood tests of survivors and non-survivors  
Median (IQR)  Survivors (n = 45) Non-survivors (n = 27) 
Albumin (g/L) 24.0 (21.5-26.5) 25.0 (22.0-27.0) 
Bilirubin (µmol/L) 98.5 (50.5-244.5) 107.0 (64.0-275.0) 
White cell count  
(106 cells/ml) 
9.1 (6.2-12.6) 8.5 (5.7-11.5) 
C-reactive Protein (mg/L) 29.5 (11.0-55.0) 37.5 (16.0-67.0) 
Creatinine (mmol/L) 65.0 (52.0-81.0) 80.0 (63.0-118.0) 
INR 1.7 (1.4-1.8) 1.7 (1.4-2.2) 
Temperature (°C) 36.8 (36.5-37.5) 36.5 (36.1-36.8) 
 
 



SUPPLEMENTAL METHODS 
 
Criteria for decompensation of liver cirrhosis 
These were defined as acute onset or worsening of complications of cirrhosis including 
gastroesophageal haemorrhage, jaundice, alcoholic hepatitis, ascites, hepatic encephalopathy, 
sepsis or infection including spontaneous bacterial peritonitis, hepatorenal syndrome or renal 
dysfunction. 
Renal dysfunction was defined as an increase in serum creatinine level by ≥50% compared to 
creatinine level at baseline. Infection was defined as when a patient was prescribed a new 
antibiotic(s) and clinical data was recorded to subsequently categorise infection according to 
standard international criteria 1. Both of these endpoints were recorded no earlier than 48 hours 
after the onset of albumin treatment.  
 
Monocyte-derived macrophages (MDM) ex-vivo immune function assay 
MDMs obtained from healthy volunteers 2,3 were sensitized with plasma for 30 minutes at 37 °C 
and then stimulated with 100 ng/ml of lipopolysaccharide (LPS, Salmonella abortus equi S-
form,[TLRgrade™], Enzo Life Science, United Kingdom). Cell supernatants were collected at 4 
and 24 hours post-stimulation and stored at - 80°C.  Tumor Necrosis Factor (TNF)-α (4 hour 
samples) and IL-10 levels (24 hour samples) in supernatants were quantified by enzyme-linked 
immunosorbent assay (DuoSet ELISA, R&D Systems, USA) following manufacturer protocol. 
For selected experiments pan-PGE2 receptors were antagonised with 50µM AH6809 (EP1-3 
antagonist) (Cayman Chemicals, MI, USA) and 10µM MF498 (EP4 antagonist) (Cayman 
Chemicals, MI, USA), prior to plasma sensitization and LPS stimulation. 
For soluble IL-4 blocking  experiments, plasma from healthy volunteers or ATTIRE patients was 
incubated with either 1 µg/ml human IL-4 antibody (clone #34019, R&D Systems, USA) or 
mouse IgG2B isotype control (clone #20116, R&D Systems, USA) for 1 hour at 37 °C prior to 
MDM sensitization. In other experiments recombinant human IL-4 (Peprotech, NJ, USA) at 
different concentrations were added to healthy volunteer plasma. 
 
Plasma soluble mediator analysis 
Circulating albumin levels were measured at local hospital laboratories as part of the study 
protocol. Plasma LPS-binding protein (LBP) levels were quantified by ELISA following 
manufacturer’s protocol (R&D Systems, USA). Briefly, plasma was thoroughly thawed and 
diluted in reagent diluent (Phosphate Buffer Saline containing 5% bovine serum albumin) prior 
to being added to antibody-coated microplates. Quantification of immobilized antibody-enzyme 
conjugates was performed by monitoring horseradish peroxidase activities in the presence of 
the substrate 3, 3’, 5, 5’-tetramethylbenzidine; which was measured spectrophotometrically by 
the increased absorbency at 450 nm. 
Levels of multiple cytokine and chemokine levels were measured in patient and healthy 
volunteer plasma by electrochemiluminescence detection using the V-Plex Pro-inflammatory 
panel 1, Cytokine Panel 1 and Chemokine Panel 1 kits from Meso Scale Discovery (MSD, Meso 
Scale Discovery, Rockville, Maryland, USA). Data were acquired using a SECTOR S 6000 plate 
reader (MSD). 
Plasma lipid mediators levels were quantified by High Performance Liquid Chromatography as 
described in 3. 
 
Western Blotting 
Peripheral blood mononuclear cells (PBMC) were obtained from acutely decompensated 
inpatients admitted to University College Hospital with complications of cirrhosis or healthy 
volunteers. Full NHS Research Ethics Committee ethical approval was obtained (REC 
Reference number 15/LO/0800). 
Briefly, venous blood was collected in vacutainer tubes containing heparin and layered onto 15 
mL Ficoll-Paque PLUS (GE Healthcare, United Kingdom).  PBMCs were separated by density 
gradient centrifugation and residual erythrocyte contamination was removed using Ammonium-
Chloride-Potassium (ACK) lysis buffer (Lonza, Switzerland).  Cell pellets were then lysed in 
RIPA buffer (Sigma Aldrich, MO, USA) supplemented with protease inhibitors. 30 µg of cell 
lysates were then loaded onto a 4-15% Tris-Glycine gel (Bio-Rad, CA, USA), electrophoresed 
and transferred onto a PVDF membrane. Membrane was immunoblotted with rabbit monoclonal 
anti-IL4 antibody (ab62351, Abcam, United Kingdom) and mouse monoclonal anti-GAPDH (sc-
32233, Santa Cruz Biotechnology, TX, USA). Anti-rabbit (sc-2301, Santa Cruz Biotechnology, 
TX, USA) or anti-mouse (NA931VS, GE Healthcare, United Kingdom) horseradish-peroxidase-
tagged antibodies were used for secondary binding and chemiluminescence (Clarity Western 
ECL, Bio-Rad, CA, USA) was used to visualise proteins. 
 
 
Statistical analysis 
Unless stated otherwise, data are presented as mean ± Standard Deviation (SD). . Two-tailed 
(unpaired) t-tests were performed when comparing two independent groups of values where a 
normal distribution was reasonable to assume.  
 
 
 
 
 
 
 
SUPPLEMENTAL REFERENCES 
1.  Bajaj JS, O’Leary JG, Reddy KR, et al. Second infections independently increase 
mortality in hospitalized patients with cirrhosis: the North American consortium for the 
study of end-stage liver disease (NACSELD) experience. Hepatology 2012;56:2328-
2335. 
2.  O’Brien AJ, Fullerton JN, Massey KA, et al. Immunosuppression in acutely 
decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 2014;20:518-523. 
3.  China L, Maini A, Skene SS, et al. Albumin Counteracts Immune-Suppressive Effects of 
Lipid Mediators in Patients With Advanced Liver Disease. Clin Gastroenterol Hepatol 
2018;16:738-747.e7. 
 
Supplemental Table 1. Plasma Lipid Mediator profiles 
 Survivors Non-survivors 
Day 1 Day 5 Day 1 Day 5 
DHA Bioactive 
Metabolome 
(pg/ml) 
Average SEM Average SEM Average SEM Average SEM 
RvD1 0.30 0.16 0.46 0.29 2.34 1.57 1.04 0.34 
RvD2 0.68 0.20 2.98 2.16 0.63 0.29 13.46 7.22 
RvD3 0.17 0.10 0.18 0.15 0.42 0.08 0.21 0.07 
RvD4 0.98 0.55 1.31 0.63 3.81 1.34 2.24 0.94 
RvD5 1.21 0.83 1.44 0.52 0.57 0.25 1.77 0.59 
RvD6 0.72 0.40 0.73 0.25 0.54 0.17 0.40 0.22 
17R-RvD1 1.00 0.81 0.11 0.06 0.21 0.17 0.38 0.15 
17R-RvD3 0.12 0.05 0.10 0.09 0.08 0.06 0.26 0.20 
 
PD1 0.84 0.46 4.74 3.98 0.80 0.52 3.39 2.05 
10S,17SdiHDHA 5.94 4.21 9.35 8.39 7.75 4.49 3.60 1.78 
17R-PD1 0.51 0.25 0.89 0.48 0.27 0.19 0.20 0.07 
 
PCTR1 1.24 1.38 1.46 1.21 1.66 1.85 0.93 0.99 
PCTR2 1.22 0.89 123.44 117.81 0.00 0.00 25.12 26.75 
PCTR3 16.51 18.45 2.55 2.75 0.00 0.00 43.99 30.11 
 
MaR1 0.00 0.00 1.44 1.01 0.00 0.00 3.81 1.65 
MaR2 0.79 0.51 0.29 0.14 0.31 0.22 0.78 0.37 
7S,14S-diHDHA 8.74 6.73 9.99 4.36 7.45 6.34 15.89 7.31 
22-OH-MaR1 0.00 0.00 1.12 1.10 0.91 0.65 4.73 2.21 
4S,14S-diHDHA 0.59 0.42 0.36 0.15 0.13 0.08 0.14 0.08 
 
MCTR1 19.54 21.85 0.82 0.89 9.04 10.11 0.00 0.00 
MCTR2 2.26 2.53 49.75 53.73 0.00 0.00 0.22 0.23 
MCTR3 46.72 50.54 22.74 21.50 16.75 13.01 1.46 1.56 
n-3 DPA 
Bioactive 
Metabolome 
(pg/ml) 
Survivors Non-survivors 
Day 1 Day 5 Day 1 Day 5 
Average SEM Average SEM Average SEM Average SEM 
RvT1 0.38 0.38 0.67 0.41 0.35 0.25 1.55 0.88 
RvT2 0.12 0.07 0.41 0.32 1.48 1.40 1.40 1.05 
RvT3 0.48 0.14 5.06 5.14 0.73 0.31 1.00 0.55 
RvT4 0.44 0.24 0.42 0.21 0.60 0.40 0.74 0.39 
 
RvD1n3 DPA 0.77 0.28 0.48 0.09 0.47 0.19 1.81 0.61 
RvD2n3 DPA 0.38 0.27 1.37 0.87 1.09 0.50 3.32 2.15 
RvD5n3 DPA 1.05 0.55 1.49 0.79 1.18 0.88 1.21 0.96 
 
PD1n3 DPA 0.81 0.47 0.37 0.17 1.22 0.23 0.30 0.22 
10S,17S-
diHDPA 
0.60 0.30 0.12 0.13 0.62 0.43 0.48 0.47 
PD2n3 DPA 0.26 0.20 0.41 0.18 0.39 0.35 0.06 0.06 
 
MaR1n3 DPA 0.36 0.40 1.06 0.50 0.20 0.22 1.08 0.71 
7S,14S-diHDPA 0.37 0.26 0.19 0.20 1.34 1.14 0.89 0.49 
MaR2n3 DPA 5.58 1.92 5.36 1.90 6.62 3.72 8.67 5.95 
EPA Bioactive 
metabolome 
(pg/ml) 
Survivors Non-survivors 
Day 1 Day 5 Day 1 Day 5 
Average SEM Average SEM Average SEM Average SEM 
RvE1 0.71 0.59 2.62 1.17 0.46 0.45 2.51 1.31 
RvE2 0.46 0.36 0.59 0.28 0.00 0.00 3.36 3.30 
RvE3 2.00 0.68 1.98 0.59 0.00 0.00 1.73 1.49 
AA Bioactive 
Metabolome 
(pg/ml) 
Survivors Non-survivors 
Day 1 Day 5 Day 1 Day 5 
Average SEM Average SEM Average SEM Average SEM 
LXA4 0.20 0.12 1.51 1.41 0.22 0.17 0.35 0.22 
LXB4 56.89 33.64 28.43 9.18 49.68 26.23 32.28 14.62 
5S,15S-diHETE 0.67 0.75 0.70 0.55 0.94 0.51 0.46 0.24 
15-epi-LXA4 0.76 0.46 2.25 1.24 4.03 2.48 4.85 2.73 
15-epi-LXB4 0.00 0.00 5.99 3.66 0.93 0.80 1.39 1.04 
 
LTB4 59.61 39.43 19.08 10.53 13.32 7.91 7.38 2.79 
5S,12S-diHETE 0.57 0.64 0.85 0.44 2.51 1.95 3.91 2.56 
20-OH-LTB4 39.32 24.93 41.82 25.07 7.22 4.76 19.70 15.52 
 
LTC4 104.49 42.32 245.07 58.23 140.27 60.57 380.26 212.29 
LTD4 2.28 1.08 2.57 2.48 2.46 2.32 5.54 3.88 
LTE4 99.42 75.69 44.22 22.49 17.65 5.42 15.99 2.57 
 
PGD2 47.06 32.13 13.55 5.12 26.30 15.98 10.14 4.67 
PGE2 158.05 127.58 49.01 23.36 62.15 60.14 11.75 2.49 
PGF2a 92.10 66.27 32.92 16.63 129.55 135.36 15.65 4.06 
TXB2 760.53 562.20 280.12 158.57 441.14 291.99 761.01 632.45 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 2.  
  
 
 
 
 
 Survivors Non-survivors 
HV 
 Day 1 Day 5 Day 1 Day 5 
Plasma 
analyte  pg/ml SD pg/ml SD pg/ml SD pg/ml SD pg/ml SD 
CCL2 378.4 174.6 323.7 131.1 266.1 192.9 319.4 194.3 159.4 51.9 
CCL3 41.8 17.8 31.6 46.4 38.9 16.4 27.4 12.9 13.9 2.8 
CCL4 159 114.1 135.1 100.8 99.5 19.8 92.1 27.6 34.9 5.8 
CCL17 80.3 12.2 126 34.2 157.3 30.5 86.9 17.1 50.3 21.3 
CCL22 378.9 74 764.5 164.6 932 136.8 408 62.4 838.7 200.3 
Eotaxin 914.8 480.8 885.1 315.4 842.2 459.4 1047.8 429.6 647.4 126.4 
Eotaxin-3 138.5 66.1 150.7 59.3 117.4 43.2 142.7 60.7 647.4 126.4 
GM-CSF 0.18 0.04 0.17 0.04 0.18 0.04 0.10 0.03 0.06 0.03 
IFN-γ 8.54 2.53 9.14 2.18 3.29 1.05 6.16 2.24 1.78 0.99 
IL-1α 2.05 3.21 2.67 1.82 4.85 5.2 4.52 3.70 n/a n/a 
IL-1β 0.59 0.14 1.7 0.42 0.41 0.12 1.34 0.95 n/a n/a 
IL-2 0.62 0.27 0.89 0.35 0.36 0.23 0.58 0.33 1.17 1.06 
IL-4 0.082 0.02 0.19 0.05 0.065 0.02 0.056 0.01 0.03 0.01 
IL-5 0.73 0.5 1.17 1 0.67 0.26 1.04 0.74 0.56 0.20 
IL-6 17.5 7.16 20.68 5.08 26.3 9.66 20.94 9.5 0.13 0.04 
IL-7 6.43 1.49 4.95 0.84 5.20 1.07 5.32 0.91 2.93 0.63 
IL-8 265.4 35 359.3 202.4 261.1 68.7 156.8 34.9 3.6 1.14 
IL-10 1.06 0.24 1.03 0.34 1.13 0.28 1.63 0.43 0.13 0.07 
IL-12p70 0.45 0.37 0.58 0.60 0.29 0.07 0.58 0.60 0.18 0.07 
IL-13 2.12 1.53 2.82 2.13 1.59 0.85 2.19 2.85 0.72 0.39 
IL-15 7.28 1.7 5.73 1.9 7.36 4.13 6.0 1.58 2.68 0.51 
IL-16 358.9 218.6 341.3 250.2 472.3 543.05 511.2 344.1 142.8 35.17 
IL-17 5.97 1.86 6.01 1.78 3.26 0.39 2.59 0.28 2.18 0.74 
IL-23 99.23 124.6 90.1 61.54 94.68 79.16 64.9 54.9 105.7 52.3 
IP-10 1104.1 1040.9 1085.2 568.5 729.3 499.3 1085.2 568.5 220.4 63.3 
MCP-4 334.5 81.8 443.4 51 344.3 45.6 636.6 80.9 243.4 96.8 
TNF-α 4.45 0.83 4.05 0.97 5.52 1.44 4.33 0.78 1.26 0.11 
TNF-β 0.53 0.17 0.42 0.10 0.52 0.14 0.48 0.11 0.29 0.06 
VEGF 130.9 163.3 125.7 157.1 32.71 20 103.4 172.8 12.38 2.04 
Supplemental Figure 1 
 
A-C) 2-dimentional score plot (Left) and loading plot (Right) of samples at Day 1 (A), Day 5 (B), 
Day 10 (C) and Day 15 (D). Gray ellipse in the score plot denotes 95% confidence regions. Day 
1: survivors n = 5, non-survivors n = 5; Day 10: survivors n = 6, non-survivors n = 7; Day 15: 
survivors n = 5, non-survivors = 4. 
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A) Plasma cytokine levels on day 1 and day 5 samples from survivors (n = 8-9) and non-
survivors (n = 7-8). Results are expressed as pg / mL, mean ± SEM. Dotted line represents 
mean levels on healthy volunteer plasma (n = 5). 
B) IL-4 was detected by immunoblotting on peripheral blood mononuclear cells of acutely 
decompensated (AD) patients and healthy volunteers (HV). Expression of GAPDH was used as 
input loading control.   
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Day 5 plasma IL-4 levels correlations with baseline clinical characteristics. Data represents 
product of Pearson’s Correlation Coefficient (n = 13-16). Best-fit linear slope is also included. 
 
